Role of B7‐H3 in predicting response to neoadjuvant chemotherapy in muscle‐invasive bladder cancer
Abstract Background Neoadjuvant platinum‐based chemotherapy offers a modest survival advantage in muscle‐invasive bladder cancer (MIBC) for patients with pathologic response. B7‐H3 (CD276), an immune checkpoint overexpressed in various cancers, including urothelial‐cell carcinoma (UCC), has been ass...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-11-01
|
| Series: | BJUI Compass |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/bco2.418 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592030377705472 |
|---|---|
| author | Ekamjit S. Deol Reza Nabavizadeh Roxane R. Lavoie Mihai G. Dumbrava Edlira Horjeti Prabin Thapa John C. Cheville Igor Frank Fabrice Lucien |
| author_facet | Ekamjit S. Deol Reza Nabavizadeh Roxane R. Lavoie Mihai G. Dumbrava Edlira Horjeti Prabin Thapa John C. Cheville Igor Frank Fabrice Lucien |
| author_sort | Ekamjit S. Deol |
| collection | DOAJ |
| description | Abstract Background Neoadjuvant platinum‐based chemotherapy offers a modest survival advantage in muscle‐invasive bladder cancer (MIBC) for patients with pathologic response. B7‐H3 (CD276), an immune checkpoint overexpressed in various cancers, including urothelial‐cell carcinoma (UCC), has been associated with chemoresistance and poor oncologic outcomes. We aimed to explore if B7H3 expression on bladder biopsy samples was a predictive biomarker for pathologic response to neoadjuvant platinum‐based chemotherapy. Methods This was a retrospective cohort study among MIBC patients receiving neoadjuvant platinum‐based chemotherapy followed by radical cystectomy. All patients underwent routine preoperative biopsy of their tumour. Immunohistochemistry was used to evaluate B7‐H3 expression from pre‐operative specimens. The primary outcome of interest was pathologic complete response (pCR). Statistical analysis included Mann–Whitney U test, Fisher's exact test, Kaplan–Meier method, and Cox regression for survival analysis. Results Among 87 patients analysed, high B7‐H3 expression was found in 44.8% (n = 39) of patients. The median follow‐up periods were similar between the high and low B7‐H3 groups (high expression; 4.29 years [SD 3.04], low expression 3.94 years [SD 3.04], p = 0.60). Only 20.5% of patients with high B7‐H3 expression achieved pCR, compared to 41.7% in the low expression group (p = 0.04). Cox regression showed no significant differences in recurrence‐free or cancer‐specific survival between the high and low B7‐H3 expression groups (p > 0.05). Conclusion High B7‐H3 expression is associated with a reduced likelihood of achieving pCR in MIBC patients undergoing neoadjuvant chemotherapy. This suggests B7‐H3's potential as a predictive biomarker for chemotherapy response. Further research is needed to explore the role of B7‐H3 on platinum‐based chemotherapy response in urothelial cancer. |
| format | Article |
| id | doaj-art-d310f57a069149ad9605a1c2f4abd6e2 |
| institution | Kabale University |
| issn | 2688-4526 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | BJUI Compass |
| spelling | doaj-art-d310f57a069149ad9605a1c2f4abd6e22025-01-22T02:21:03ZengWileyBJUI Compass2688-45262024-11-015111166117210.1002/bco2.418Role of B7‐H3 in predicting response to neoadjuvant chemotherapy in muscle‐invasive bladder cancerEkamjit S. Deol0Reza Nabavizadeh1Roxane R. Lavoie2Mihai G. Dumbrava3Edlira Horjeti4Prabin Thapa5John C. Cheville6Igor Frank7Fabrice Lucien8Department of Urology Mayo Clinic Rochester Minnesota USADepartment of Urology Mayo Clinic Rochester Minnesota USADepartment of Urology Mayo Clinic Rochester Minnesota USADivision of Experimental Pathology Mayo Clinic Rochester MNDepartment of Urology Mayo Clinic Rochester Minnesota USADepartment of Urology Mayo Clinic Rochester Minnesota USADivision of Experimental Pathology Mayo Clinic Rochester MNDepartment of Urology Mayo Clinic Rochester Minnesota USADepartment of Urology Mayo Clinic Rochester Minnesota USAAbstract Background Neoadjuvant platinum‐based chemotherapy offers a modest survival advantage in muscle‐invasive bladder cancer (MIBC) for patients with pathologic response. B7‐H3 (CD276), an immune checkpoint overexpressed in various cancers, including urothelial‐cell carcinoma (UCC), has been associated with chemoresistance and poor oncologic outcomes. We aimed to explore if B7H3 expression on bladder biopsy samples was a predictive biomarker for pathologic response to neoadjuvant platinum‐based chemotherapy. Methods This was a retrospective cohort study among MIBC patients receiving neoadjuvant platinum‐based chemotherapy followed by radical cystectomy. All patients underwent routine preoperative biopsy of their tumour. Immunohistochemistry was used to evaluate B7‐H3 expression from pre‐operative specimens. The primary outcome of interest was pathologic complete response (pCR). Statistical analysis included Mann–Whitney U test, Fisher's exact test, Kaplan–Meier method, and Cox regression for survival analysis. Results Among 87 patients analysed, high B7‐H3 expression was found in 44.8% (n = 39) of patients. The median follow‐up periods were similar between the high and low B7‐H3 groups (high expression; 4.29 years [SD 3.04], low expression 3.94 years [SD 3.04], p = 0.60). Only 20.5% of patients with high B7‐H3 expression achieved pCR, compared to 41.7% in the low expression group (p = 0.04). Cox regression showed no significant differences in recurrence‐free or cancer‐specific survival between the high and low B7‐H3 expression groups (p > 0.05). Conclusion High B7‐H3 expression is associated with a reduced likelihood of achieving pCR in MIBC patients undergoing neoadjuvant chemotherapy. This suggests B7‐H3's potential as a predictive biomarker for chemotherapy response. Further research is needed to explore the role of B7‐H3 on platinum‐based chemotherapy response in urothelial cancer.https://doi.org/10.1002/bco2.418biomarkersbladder cancercystectomyneoadjuvant chemotherapy |
| spellingShingle | Ekamjit S. Deol Reza Nabavizadeh Roxane R. Lavoie Mihai G. Dumbrava Edlira Horjeti Prabin Thapa John C. Cheville Igor Frank Fabrice Lucien Role of B7‐H3 in predicting response to neoadjuvant chemotherapy in muscle‐invasive bladder cancer BJUI Compass biomarkers bladder cancer cystectomy neoadjuvant chemotherapy |
| title | Role of B7‐H3 in predicting response to neoadjuvant chemotherapy in muscle‐invasive bladder cancer |
| title_full | Role of B7‐H3 in predicting response to neoadjuvant chemotherapy in muscle‐invasive bladder cancer |
| title_fullStr | Role of B7‐H3 in predicting response to neoadjuvant chemotherapy in muscle‐invasive bladder cancer |
| title_full_unstemmed | Role of B7‐H3 in predicting response to neoadjuvant chemotherapy in muscle‐invasive bladder cancer |
| title_short | Role of B7‐H3 in predicting response to neoadjuvant chemotherapy in muscle‐invasive bladder cancer |
| title_sort | role of b7 h3 in predicting response to neoadjuvant chemotherapy in muscle invasive bladder cancer |
| topic | biomarkers bladder cancer cystectomy neoadjuvant chemotherapy |
| url | https://doi.org/10.1002/bco2.418 |
| work_keys_str_mv | AT ekamjitsdeol roleofb7h3inpredictingresponsetoneoadjuvantchemotherapyinmuscleinvasivebladdercancer AT rezanabavizadeh roleofb7h3inpredictingresponsetoneoadjuvantchemotherapyinmuscleinvasivebladdercancer AT roxanerlavoie roleofb7h3inpredictingresponsetoneoadjuvantchemotherapyinmuscleinvasivebladdercancer AT mihaigdumbrava roleofb7h3inpredictingresponsetoneoadjuvantchemotherapyinmuscleinvasivebladdercancer AT edlirahorjeti roleofb7h3inpredictingresponsetoneoadjuvantchemotherapyinmuscleinvasivebladdercancer AT prabinthapa roleofb7h3inpredictingresponsetoneoadjuvantchemotherapyinmuscleinvasivebladdercancer AT johnccheville roleofb7h3inpredictingresponsetoneoadjuvantchemotherapyinmuscleinvasivebladdercancer AT igorfrank roleofb7h3inpredictingresponsetoneoadjuvantchemotherapyinmuscleinvasivebladdercancer AT fabricelucien roleofb7h3inpredictingresponsetoneoadjuvantchemotherapyinmuscleinvasivebladdercancer |